Drug devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.
The global drug device combination product market size is expected to reach USD 176 billion by 2024. Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.
Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.
Report Sample includes:
- Table of Contents
- List of Tables & Figures
- Research Methodology
Get FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-drug-device-combination-s-2019-411
The global Drug Device Combination Products market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019–2025.
This report focuses on Drug Device Combination Products volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drug Device Combination Products market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Drug Device Combination Products in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Drug Device Combination Products manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
- Abbott Laboratories
- Terumo Corporation
- Stryker Corporation
- Mylan N.V.
- St.Jude Medical, Inc.
- Allergan, Plc
- Boston Scientific Corporation
- Novartis AG
- Teleflex Incorporated
- C.R. Bard, Inc.
- W.L.Core & Associates, Inc.
Segment by Regions
- North America
- Southeast Asia
Segment by Type
- Drug-eluting stents
- Prefilled syringes
- Wearable injectors
- Insulin injector drug
Segment by Application
- Hospitals and Clinics
- Medical Laboratories
Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/global-drug-device-combination-s-2019-411
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports